vTv Therapeutics Inc. (VTVT)
NASDAQ: VTVT · IEX Real-Time Price · USD
20.40
-1.00 (-4.67%)
Jul 19, 2024, 4:00 PM EDT - Market closed
vTv Therapeutics Revenue
vTv Therapeutics had revenue of $1.00M in the twelve months ending March 31, 2024, with 5,455.56% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $1.00M.
Revenue (ttm)
$1.00M
Revenue Growth
+5,455.56%
P/S Ratio
49.63
Revenue / Employee
$62,500
Employees
16
Market Cap
49.63M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 2.02M | -1.99M | -49.61% |
Dec 31, 2021 | 4.01M | -2.41M | -37.56% |
Dec 31, 2020 | 6.41M | 3.65M | 132.05% |
Dec 31, 2019 | 2.76M | -9.67M | -77.77% |
Dec 31, 2018 | 12.43M | 12.14M | 4,172.85% |
Dec 31, 2017 | 291.00K | -343.00K | -54.10% |
Dec 31, 2016 | 634.00K | 115.00K | 22.16% |
Dec 31, 2015 | 519.00K | -1.03M | -66.49% |
Dec 31, 2014 | 1.55M | 573.00K | 58.71% |
Dec 31, 2013 | 976.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Inotiv | 552.74M |
Cidara Therapeutics | 46.38M |
Bionano Genomics | 37.47M |
Ocuphire Pharma | 19.01M |
DURECT | 8.32M |
VTVT News
- 27 days ago - vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes - GlobeNewsWire
- 7 weeks ago - CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING - PRNewsWire
- 2 months ago - vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT - PRNewsWire
- 4 months ago - vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes - GlobeNewsWire
- 5 months ago - vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference - GlobeNewsWire
- 5 months ago - vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund - GlobeNewsWire